Cardiol Therapeutics Inc. CRDL
1.01 USD -0.01 (-0.98%)
At closeNov 12, 2026, 7:25 AM EST
1.01 0.00 0.00%
Pre-market · Nov 12, 7:25 AM ET
1.01 Day range 1.07
0.88 52-week range 2.34
- YTD
- +5.87%
- 1 year
- -2.88%
News
benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Enrollment Progress And Plans To Expand Its MAVERIC Phase III Trial Evaluating CardiolRx For Risk Reduction Of Recurrence In Patients With Recurrent Pericarditis As of September 23, 2026, 110 patients have been enrolled in MAVERIC, achieving the Company's original recruitment target ahead of its end-of-September guidance."A blinded review of events in MAVERIC…
benzinga.com Cardiol Therapeutics Files $150M Base Shelf Prospectus, Enabling Future Offerings Of Shares, Debt, Warrants And Other Securities Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular session. The market value of their outstanding shares is at $2.1 billion. SCYNEXIS (NASDAQ:SCYX) stock…
benzinga.com Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $10 Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $8 to $10.- benzinga.com HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target HC Wainwright & Co. analyst Brandon Folkes reiterates Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and maintains $9 price target.
benzinga.com Cardiol Therapeutics Announces Publication Of Phase II MAvERIC Study Results In The Journal of the American Heart Association The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session 
benzinga.com Why MongoDB Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket 
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 200 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 78 companies made new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 838 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's trading, 528 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 404 stocks made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 44 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 402 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 198 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
benzinga.com 52 Biggest Movers From Yesterday Gainers Zogenix, Inc. (NASDAQ: ZGNX) shares surged 65.7% to close at $25.92 on Wednesday after the company announced it will be acquired by UCB for approximately $1.9 billion.